In part 1 of this 4 part series, Michael Thorpy, MD, talks about salt intake and how health guidelines and individual habits shape what kind of medication is right for patients with sleep disorders like excessive daytime sleepiness or narcolepsy.
Readers can also check out part 2 now.
Understanding existing patient sodium intake and medication availability is key in prescribing medications to patients with sleep disorders like excessive daytime sleepiness or narcolepsy, explains Michael Thorpy, MD, professor of neurology at the Albert Einstein College of Medicine, and director of the Sleep Disorder Center at Montefiore Medical Center.
Transcript
Why is it important to consider low-sodium sleep medications and salt/sodium intake with therapeutics and not only food for patients with sleep disorders?
There's an increasing awareness about the importance of salts in our diets. It seems as though every few years there are recommendations that are made about limiting the amount of salt intake that we take. At the present time, the American Heart Association recommends that people should only ingest about 2300 mg of salt a day. Ideally, it should be even less than that at 1500 mg.
However, some of the medications do have a fairly high salt content, and the one that's of particular concern in sleep medicine is the salt content of a medication that's used for the treatment of narcolepsy and other disorders of excessive daytime sleepiness. There is a formulation called sodium oxybate, which at the highest recommended dose contains 1940 mg of salt, or sodium. It is estimated that the average intake of salt in the United States is 3400 mg a day. If somebody is taking the maximum dose of sodium oxybate, then they're getting probably over 5000 mg of salt a day. That amount of salt seems to be somewhat excessive.
So, there is some concern about that, and new formulations of the sodium oxybate have been developed that have a much lower sodium content, so as to prevent people from having an excessive amount of salt intake.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Insurance Payer Is Associated With Length of Stay After Traumatic Brain Injury
February 21st 2025Among hospitalized patients with traumatic brain injury, Medicaid fee-for-service was associated with longer hospital stays than private insurance and Medicaid managed care organizations.
Read More
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More